by wohlenberg@vierviertel.com | 07.07.2021 | News, 2021
CORAT Therapeutics GmbH announces partnership with Dermapharm Holding SE
by wohlenberg@vierviertel.com | 22.06.2021 | News, 2021
CORAT antibody COR-101 recognizes the current “Indian” mutant B.1.617
by wohlenberg@vierviertel.com | 03.06.2021 | News, 2021
CORAT Therapeutics secures additional funding
by wohlenberg@vierviertel.com | 11.05.2021 | News, 2021
CORAT’s CEO Dr. Andreas Herrmann and CSO Dr. André Frenzel comment in international television on the start of clinical studies with CORAT Therapeutics SARS-CoV-2 neutralising antibody COR-101 against COVID-19 in hospitalized patients. The article can be viewed...
by wohlenberg@vierviertel.com | 23.04.2021 | News, 2021
Tübingen, Germany, 23.4.2021 – CORAT Therapeutics initiated a Phase Ib/II clinical trial evaluating the safety, tolerability, and efficacy of COR-101 in a total of 45 patients at five sites in Germany CORAT Therapeutics GmbH announced the start of a clinical...
by wohlenberg@vierviertel.com | 16.03.2021 | News, 2021
CORAT Therapeutics GmbH obtained regulatory authorization for clinical phase Ib/II trial with the SARS-CoV-2 neutralizing human antibody COR-101. The study (ClinicalTrials.gov ID: NCT04674566) is a randomized, double-blind, placebo-controlled, parallel-group,...